Kyle Jaeger is a Managing Editor at Marijuana Moment. He focuses on cannabis and psychedelics, exploring topics such as psychedelic research, therapy, and cannabis regulation, while also delving into agriculture and farming related to these areas. His work has been featured in FILTER, 420 Intel, Upworthy, and Marijuana Moment.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kyle Jaeger's coverage primarily focuses on marijuana legalization, state laws, and congressional actions in the United States. Given his focus on government announcements and legal policy regulation related to cannabis, he is likely to be receptive to pitches from experts in law or public policy with specific insights into cannabis legislation at the state or federal level.
Pitches offering analysis of recent legislative developments or expert commentary on the intersection of healthcare and pharmaceuticals with marijuana legalization may also align well with Kyle’s coverage interests. Additionally, given his interest in government and politics themes, he might appreciate pitches related to the political dynamics surrounding cannabis legislation at both state and national levels.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kyle Jaeger
A coalition of anti-marijuana organization is suing the Trump administration over a novel initiative set to launch this week to widen the availability
By: Kyle Jaeger
Hawaii senators are sending a message to the governor, state attorney general and health department to recognize their “clear legislative stance” in support of requesting an exemption from the Drug Enforcement Administration (DEA) stipulating that Hawaii is permitted to run its medical cannabis program without federal interference.
By: Kyle Jaeger
Maryland House lawmakers have approved a Senate-passed bill to extend a psychedelics task force through the end of 2027 to develop updated recommendations on expanding therapeutic access to the novel drugs and potentially creating a regulatory framework for broader legalization.
By: Kyle Jaeger
Virginia officials are ramping up hiring for a variety of cannabis regulatory roles as the state's pro-legalization governor prepares to take action on a bill to allow recreational sales , in addition to several other reform proposals that lawmakers have sent to her desk.
By: Kyle Jaeger
FBI agents received specific guidance prohibiting them investing in marijuana companies—but not necessarily those that make hemp or CBD products—according to a 2022 memo that the agency released last week for reasons that are unclear.
By: Kyle Jaeger
Congressional lawmakers were recently presented with a unique argument in favor of expanding therapeutic access to cannabis and rescheduling marijuana under federal law: Doing so could mitigate threats associated with Chinese Community Party (CCP) operatives.
By: Kyle Jaeger
Advocates have long argued that marijuana legalization is a superior alternative to criminalization. But while that sentiment prevails with the public and a growing number of lammakers, a leading drug policy reform group says it's nonetheless important to recognize and address potential public health impacts of consumer trends in state-regulated markets—including the rise of high-potency THC products.
By: Kyle Jaeger
There's been a new breakthrough in the development of a marijuana breathalyzer, with a study partly funded by the Justice Department showing a potential pathway for a “portable, low cost” device that looks like an inhaler for asthma, built with 3-D printed material that can detect delta-9 THC without secondary lab analysis.
By: Kyle Jaeger
China's agricultural history with cannabis is deeper than previously believed, with a new study placing the staple crop among “the five grains” (alongside rice and barely, for example) that were foundational to the ancient Eurasian economy and “deeply integrated into the daily lives of the inhabitants.”
Minnesota House lawmakers have voted to legalize the regulated therapeutic use of psilocybin for adults 21 and older.
